Romosozumab (Evenity)
Canadian Journal of Health Technologies · 13.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses romosozumab 105 mg/1.17 mL prefilled syringe for subcutaneous injection. Type of review: Request for Advice Requester: Formulary Working Group Indication under consideration: Osteoporosis
Zitieren
APA
CDA-AMC (2026). Romosozumab (Evenity). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1537
Vancouver
CDA-AMC. Romosozumab (Evenity). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1537
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Romosozumab (Evenity)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1537}
}
EUVIMED